Interview with Prof. Dr.-Ing. Christoph Benk and Jörg Ronde, Resuscitec GmbH, at Venture Capital Magazin
“Originally, it wasn’t even planned that we would treat COVID patients”
Resuscitec GmbH was founded in 2010 with the vision of pushing the existing limits of resuscitation as far as possible. Today, the CARL therapy developed by the company enables a significant improvement in resuscitation outcomes, even long-lasting cardiovascular arrest. The CARL system has also been successfully used in the treatment of COVID patients. Read the full article here.